Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 5/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1024886 | 1.00 | F10 (0.43) | F10MAPK1HPGDTSHRLMNA | |
| SCHEMBL1024324 | 0.95 | MAPK1 (0.40) | F10MAPK1HPGDTSHRLMNA | |
| SCHEMBL3479847 | 0.95 | MAPK1 (0.40) | F10MAPK1HPGDTSHRLMNA | |
| SCHEMBL15731743 | 0.79 | F10 (0.48) | F10MAPK1HPGDTSHRLMNA | |
| SCHEMBL1023879 | 0.78 | F10 (0.75) | F10 | |
| SCHEMBL4458638 | 0.76 | MAPK1 (0.44) | F10MAPK1HPGDTSHRLMNA | |
| SCHEMBL78671 | 0.76 | HPGD (0.49) | F10MAPK1HPGDTSHRLMNA | |
| SCHEMBL4557626 | 0.75 | MAPK1 (0.44) | F10MAPK1HPGDTSHRLMNA | |
| SCHEMBL78765 | 0.75 | MAPK1 (0.43) | F10MAPK1HPGDTSHRKDM4E | |
| SCHEMBL3151178 | 0.75 | MAPK1 (0.42) | F10MAPK1HPGDTSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1945634-B1 | PHENYLENEBISOXAZOLIDINE DERIVATIVES AND THEIR USE AS ANTICOAGULANTS | BAYER SCHERING PHARMA AG (DE) | 2011-01-19 | — | — | EP | disclosed |
| US-20100041646-A1 | Phenylene-Bis-Oxazolidine Derivatives and Their Use as Anticoagulants | BAYER HEALTHCARE AG (DE) | 2010-02-18 | — | — | US | disclosed |
| US-20100041646-A1 | Phenylene-Bis-Oxazolidine Derivatives and Their Use as Anticoagulants | BAYER HEALTHCARE AG (DE) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041646-A1 | Phenylene-Bis-Oxazolidine Derivatives and Their Use as Anticoagulants | SELP, SERPINC1, F2 | F10 346/4885MAPK1 1561/4885HPGD 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.